This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Grifols Has Acquired 51% Of The Capital Of Araclon Biotech To Ensure The Viability Of The Purchased Company Projects

BARCELONA, Spain, March 15, 2012 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), the world's third largest plasma product manufacturer and a pioneer in the research and development of therapeutic alternatives designed to contribute to both scientific and social development, has acquired 51% of the equity of Zaragoza-based company Araclon Biotech, ensuring the viability of its projects and the future of the company.


Araclon Biotech was created in 2004 as a spin-off from the University of Zaragoza, and specializes in the research and development of therapies and diagnostic methods for neurodegenerative diseases, although it is currently focusing on Alzheimer's disease (AD), a condition for which there is no cure and of which there are around 350,000 to 380,000 sufferers in Spain[1] and over 25 million in the world[2].

Grifols completed the operation by acquiring a stake in the company through Gri-Cel S.A., an investment vehicle created in 2010 to promote the group's participation in fields of medicine which lie outside the scope of its main activities, such as advanced therapies.

Following the purchase, Grifols has become Araclon Biotech's largest shareholder, with a 51% holding, while other founding partners retain 49% of the capital.

The addition of Grifols to the shareholders of Araclon Biotech will guarantee the company's future and enable it to continue to promote its R&D projects, focusing in particular on two research lines:
  1. The diagnosis of AD: Using a kit patented for the detection of amyloid beta peptides (AB) 40 and 42 in the blood. Araclon Biotech is performing clinical studies with more than 400 individuals, the final results of which it is hoped will contribute to the development of a tool with 3 major applications: The early detection of AD (including in individuals with no symptoms) to monitor patients being treated for Alzheimer's disease and to improve the design of clinical trials on Alzheimer's disease.
  2. Treatments of AD: Based on immunotherapy. Research focused on developing a series of patented vaccines which have yielded positive results in various animal models and on which clinical trials will start soon.

Araclon Biotech also plans in the future to pursue a number of research initiatives in other neurodegenerative diseases related to illnesses such as vascular dementia, fibromyalgia and multiple sclerosis.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.32 -3.92%
YHOO $36.02 -1.40%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs